×

FierceMedicalDevices Names TYRX® as One of its “Fierce 15” Medical Device and Diagnostic Companies of 2012

TYRX on Leading Edge of Medical Devices

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- TYRX, Inc. announced today that it has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012.

FierceMedicalDevices Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year's winners based on their top management teams, notable financial backing, and promising technologies and market opportunities. TYRX was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.

“We took a close look at TYRX because they came up with something that is so straightforward and simple, but truly advances the standard of care. By sealing a pacemaker or defibrillator in the company’s AIGISRx® Antibacterial Envelope and then implanting both, a patient’s risk of infection is drastically reduced. And the company has generated serious revenue already,” said Hollmer.

The AIGISRx Envelope is specifically designed to aid in the stabilization of CIED placement as well as to help reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISRx products contain the antimicrobial agents rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including “superbugs” such as methicillin-resistant Staph. aureus (MRSA).

“FierceMedicalDevices is renowned for its advanced understanding of medical device companies and the industry as a whole,” said Robert White, President and CEO of TYRX. “Being selected as a member of the ‘Fierce 15’ is an honor that highlights TYRX’s potential to make a significant impact in the medical devices market.”

An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on clinical studies, FDA/EMEA regulations, and post-marketing. Sign up is free at http://www.fiercemedicaldevices.com/signup.

About FierceMarkets

FierceMarkets, a wholly owned subsidiary of Questex Media Group, is a leader in B2B emedia, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government, and finance industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of publications reaches more than 1.3 million executives in more than 100 countries.

Current publications include: Telecom: FierceBroadbandWireless; FierceCable; FierceDeveloper; FierceEnterpriseCommunications; FierceIPTV; FierceMobileContent; FierceOnlineVideo; FierceTelecom; FierceWireless; FierceWireless:Europe; Healthcare: FierceEMR; FierceHealthcare; FierceHealthFinance; FierceHealthIT; FierceHealthPayer; FierceMobileHealthcare; FiercePracticeManagement; Hospital Impact; Life Sciences: FierceBiomarkers; FierceBiotech; FierceBiotechIT; FierceBiotech Research; FierceCRO; FierceDrugDelivery; FierceMedicalDevices; FiercePharma; FiercePharmaManufacturing; FierceVaccines; Energy: FierceEnergy; FierceSmartgrid; Enterprise IT: FierceBigData; FierceCIO; FierceCIO:TechWatch; FierceContentManagement; FierceMobileIT; Finance: FierceComplianceIT; FierceFinance; FierceFinanceIT; Government: FierceGovernment; FierceGovernmentIT; FierceHomelandSecurity; and FierceMobileGovernment.

About TYRX, Inc.

TYRX, Inc., headquartered in Monmouth Junction, New Jersey, is a pioneer in the development, manufacture, and distribution of innovative, implantable combination drug-device products including the AIGISRx® Antibacterial Envelope. The AIGISRx Envelope is specifically designed to aid in the stabilization of CIED placement as well as to help reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISRx products contain the antimicrobial agents rifampin and minocycline, which have been shown to reduce infection by organisms representing the majority of the infections reported in CIED-related endocarditis, including “superbugs” or MRSA.*

For more information, please visit www.TYRX.com or www.HeartDeviceInfection.com.

*Data on file at TYRX and published in PACE.2009;32(7):898-907.

TYRX, Inc.
Robert White, 732-246-8676
President and Chief Executive Officer
info@TYRX.com
or
FierceMarkets
Heather Martin, 202-824-5043
heather@fiercemarkets.com

Source: TYRX, Inc.